Presentation is loading. Please wait.

Presentation is loading. Please wait.

Update of Autism Evaluation, Treatment, and Research Zachary Warren, PhD, Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum.

Similar presentations

Presentation on theme: "Update of Autism Evaluation, Treatment, and Research Zachary Warren, PhD, Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum."— Presentation transcript:

1 Update of Autism Evaluation, Treatment, and Research Zachary Warren, PhD, Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum Disorders Vanderbilt University

2 Acknowledgements VKC / TRIAD Jeremy Veenstra-Vander Weele Vanderbilt EPC Team Melissa McPheeters Nila Sathe Vanderbilt LEND Terri Urbano & Tyler Reimschisel Financial Disclosure: AHRQ, Autism Speaks, HRSA, MARI, MCHB, NIMH, NICHD, NSF, Simons Foundation

3 Outline Background and current context of ASD – Brief history – the disorders and intervention Presentation of systematic review – Early Intensive Intervention – Medical treatments Complementary and alternative approaches What do we do for the children with ASD that we serve?

4 Defining: Autism Spectrum Disorders 1943 – Leo Kanner – Infantile autism 1944 – Hans Asperger 1960s – Separation from schizophrenia 1970s – Biology / genetic underpinnings 1980 – DSM-III – Pervasive Developmental Disorders 1987 – DSM-III-R - Autistic Disorder / PDD-NOS 1994 – DSM-IV – Asperger’s Disorder

5 Our Context: What once was rare… Old estimate for autism: – ~ 1/2500 (1985) Recent estimates for autism: – ~ 1/500 (1995) Newest estimates for ASD: – 1/150 (CDC, 2007) – 1/110 (CDC, 2009) – 1/91 (NSCH, 2009) What will it be in 2012?

6 Does this child have autism? 1)Develop ranking for all children according to likelihood of an ASD diagnosis: #1 (likely has autism) to #7 (no way s/he has autism) NO TIES ITS ORDINAL RANKING 2)Assign an ASD “present” or “absent” diagnosis for each child

7 Origins of the disorder(s) Neurodevelopmental disorder: – Core neurogenetic vulnerabilities – Complex environmental X neurogenetic interactions? Evidence: Maleness (3:1 to 4:1) Familial loading/risk – Monozygotic twins: 60-95% – Sibling inheritance: 12-25% (18.7) – Population level: around 1%

8 A behaviorally based diagnosis Diagnosis is based on a pattern of symptoms in 3 domains: social impairments language/communication impairments restricted activities and interests Symptom expression is variable across children and over time

9 DSM-IV Pervasive Developmental Disorders Feature Autistic Disorder Asperger’s Disorder PDD-NOSRett’s Disorder Childhood Disinteg. Disorder Social impairment XXXXXbXb Comm. impairment XXaXa XXbXb Restricted interests/activ. XXXaXa XXbXb Onset prior to 36 months XX Average intelligence X Loss of skills XX a = one of these features must be present b = at least 2 of these features must be present

10 Towards DSM-V Distinctions can be difficult both within the spectrum and across other disorders Autism Spectrum Disorder Autistic D/OAsperger’sPDD-NOS

11 DSM-V Deficits in social communication (all 3): – Nonverbal and verbal communication deficits – Lack of social reciprocity – Failure to develop peer relationships Restricted, repetitive patterns of behavior, interest, and activities (2) – Stereotyped motor or verbal behavior; unusual sensory behavior – Excessive adherence to routines and ritualized bhx – Restricted, fixated interests Symptoms present in early childhood (manifest when social demands exceed capabilities)

12 Autism Asperger’s PDD Social Reciprocity Language/Communication Atypical behaviors/interests Why are numbers increasing: The addition of regions of diagnosis?

13 Constantino, JAACAP, 2003 Why are numbers increasing: Broadening spectrum?

14 New diagnostic measures – Autism Diagnostic Interview (1989, 1994) – Autism Diagnostic Observation Schedule (1989, 2000) Screening tools/algorithms/instruments in wide use: – MCHAT / AAP guidelines – SCQ – SRS Why are numbers increasing: Better tools?

15 Diagnostic changes – Categories – Broadening Better tools and identification process Awareness – Mental health providers, pediatricians, schools – Media, parents Other factors: Previous underestimates Methodology for obtaining epidemiological data What else??? Why are numbers increasing: Lots of reasons?

16 Developmental Impact of Intervention: Prevention of Cascading Effects?

17 The American Academy of Pediatrics recommends developmental surveillance at every well-child visit and developmental screening using formal, validated tools at 9-, 18-, and 24- or 30-month visits or whenever a parent or provider concern is expressed Reprinted from Pediatrics, 2006; 117:404-419.

18 In addition, autism- specific screenings are recommended at the 18- and 24-month visits

19 What happens after a positive screens? Ideally: Referred for evaluation of specialized team Accessibility: Resources not present Availability: Long waits (e.g., 6 - 12 months) Ideally: Appropriately intensive specialized services are rapidly initiated regardless of diagnostic status Reality: Positive screens lead can lead to long waits for diagnosis and intensive service delivery

20 Components of ‘Gold Standard’ Assessment Medical assessment Autism Diagnostic Interview – Revised (ADI-R) – Structured clinical interview – 90-180 minutes Autism Diagnostic Observation Schedule (ADOS) – Semi-structured interaction – 45 minutes / 15 minutes scoring Developmental assessment – Cognitive/IQ – Language – Adaptive behavior

21 Autism Symptoms: Assessment Framework Negative symptoms - absence of expected behaviors relative to developmental norms Positive symptoms - presence of unusual behaviors due to nature, intensity, interference with family activities

22 Autism Symptoms: Assessment Framework Negative symptoms Social behaviors Communication Positive symptoms Atypical body, sensory, play behavior

23 Social behavior is not all-or-nothing Social behaviors are not completely absent Children with autism do show social behaviors (e.g., eye contact, imitation, attachment) Social behaviors occur less consistently across people and settings (e.g., at different times, requiring greater effort)

24 Social Behavior Concerns Less responsiveness to social overtures Less participation in back-and-forth play Less “showing off” for attention Less imitation of the actions of others Less interest in other children Less functional play, doll play, imaginative play

25 Communication is not all-or-nothing Autism as a disorder of social communication – Communication vs. Language vs. Speech Young children communicate for many reasons: – To request things they want – To protest about events that displease them – To share their enjoyment with adults – To direct adult’s attention to objects or events of interest

26 Communication Vulnerabilities – Less sharing enjoyment with adults – Less directing adult attention to interests – Differences in use of gestures and gaze – Differences in terms of social communicative responses (e.g., name press, response to joint attention) – Delayed language

27 Limits of available tools Broad-based screeners – CBCL, BASC Level 1 Screening (Developmental risk vs. no) Young children: MCHAT, CHAT, PDDST School aged children: CAST Level 2 (ASD vs. other developmental concerns) – ABC, ASDS, ASSQ, GARS/GADS, SCQ Diagnostic Instruments: – ADOS, ADI-R, CARS / CARS-2 Limits of parent report: categorical and likert ratings How do tools work for younger children Are these instruments sufficient for diagnostic consultation?

28 The Challenge – Reduce waits between screening concerns and diagnosis/service delivery – Meet time demands / restrictions – Accurately identify children with/out ASD – Link children with appropriate early intervention services – Be adequately reimbursed Create a framework for performing ASD diagnostic consultations in specialty and potentially community pediatric practices that can:

29 Characteristics of STAT Screening Tool for Autism in Toddlers and Young Children (STAT) Designed as a Stage 2 screening tool (for referral populations) Consists of 12 play-based items assessing key social-communicative behaviors Takes about 15-20 minutes to administer Designed for children between 24 & 36 months – Data / modifications for above and below Simple scoring system Published psychometric data

30 Agreement 14 out of the 19 children (74%), initially classified ASD 1 of 2 (50%) non-ASD received an independent diagnosis of ASD Overall 15 out of 21 cases (71%); provider range 57-100%. Disagreements – Other delays clearly evident – Diagnostic certainty lower

31 Initial thoughts regarding potential impact 2008: 85,000 live birth @ 1/150 = 567 – Even this has changed Impact of 20 trained physicians in state – 1 assessment per week: 1040 – 1 assessment every other week: 470 Population level impact? – Expedited entry into TEIS services – Reduced waits at specialty clinics for children in need of this service. Long-term public health impact? Serious concerns about false positives as well as under-identification

32 Replication and Practice Change 27 providers – 20 Pediatricians, 3 PNPs, 3 DBPs, 1 Neurologist – M = 16 years of experience (SD=11.5, Range 2-36) 5 regional trainings in state – 8-EAST, 13 -MID, 5 - WEST 3.5 years

33 Replication and Practice Change Confirmation sample – STAT certification – Provisions for diagnostic ambiguity – Independent evaluation Assessment of practice change (1.61 years later)

34 Confirmation Sample 6 of 8 providers from mid-TN – 14 of 16 referred children independently evaluated – 13 boys, 1 girl – M = 31.71 months; Range = 24 to 42 months Agreement: 85.7% - forced model (6/7 ASD & 6/7 non-ASD) 92.9% - non-forced model

35 Practice Change - Training 10 of 13 providers participated in validation – Embedded fidelity and implementation – Diagnostic support 51.9% (14/27) total completion of fidelity/training – 4 additional STAT certified providers Regional differences: – 85.7% Mid – 40% West – 0% East

36 Practice Change - Survey

37 Clinically and statistically significant shifts (1 to 5): – Comfort discussing ASD 2.59 to 4.24 – Appropriate for child to receive diagnosis from PCP 2.35 to 4.24 No provider provided a final rating below 3 Diagnostic practice – 60% increase in diagnosis under 3 Pre to last year of practice (4.29 to 7.5). – Several providers routinely performing Hospital settings Mega-practices

38 Reported Barriers to Change Concern% Lack of appropriate referrals37.5 Financial constraints37.5 Time constraints43.8 Unable to complete training6.3 Lack of resources following diagnosis37.5 Difficulties procuring early intervention12.5

39 Should we do this? Who does this work for? – Providers – Families Does it facilitate/expedite services? Concerns – Misclassification – Family stress – Education/engagement Should we be talking about “risk”

40 The Importance of Effective Early Diagnosis and Treatment: A public health perspective Earlier diagnosis = More intervention opportunities More opportunities = Optimal intervention benefit – Core features: social communication / atypical behaviors – Cognitive and adaptive functioning – Fully integrated classroom placements – Potentially promoting optimal adaptive independence – Potentially reducing considerable lifetime cost and service system demands associated with ASD and related care

41 Costs of ASD Most quoted total lifetime costs = $3.2 million (Ganz, 2007) – Hard to know if assumptions hold / included costs Recent estimates of annual incremental costs (see Amendah et al., 2011) – $2,100 – $11,200 medical expenditures – $13,000 educational costs – $40,000-$60,000 intensive behavioral tx – $60,000-$128,000 residential costs for adults w/ASD – Productivity loss, overall lifetime costs, quantification of impact of early intervention programs

42 PartnersPediatricianProvidersFriends Social Media CDCGoogleDANAAPTVBlogosphere Autism Speaks Science in Context

43 Why Are We Doing This? Our fundamental assumption… Accurate early identification of a specific common neurodevelopmental disorder in childhood should help us connect to specific intervention and treatment options that optimize functioning for children and families

44 Treatments and Therapies 78,300,000 results (0.08 seconds) Auditory Integration Sensory Integration ABA Discrete Trial Training Lovaas/UCLA Intervention Early Start Denver Model Holding Therapy Dolphin Assisted Therapy Facilitated Communication Augmentative Communication Vision Therapy Vitamins Oxygen treatments Psychopharmacological treatments Floortime Music Therapy Social Skills Training Incidental Teaching TEACCH PECS Pivotal Response Therapy Son-Rise RDI Chelation Diets Drugs Supplements

45 Historical Perspective Not far removed from an “untreatable” era Rutter (1970): – <2% functioning “normally” – 60% requiring institutional placement/support Lovaas (1987): UCLA Young Autism Project – Intensive ABA = 9 / 19 (47%) “recovered” or “normal fx” – A breakthrough with major concerns

46 Which treatments work for specific children? Autism treatments vary widely: – Scope, Focus, Intensity, Duration, Methodology – Packages and combinations Children with ASD vary widely – Core features – Associated characteristics - IQ / challenging behavior – Additional behavioral characteristics and medical vulnerabilities – Families, communities, systems of care Different causes – different disorders – Rapid discovery of CNVs What do we want to know?

47 AHRQ Systematic Reviews Topic proposed to AHRQ – Centers for Medicare and Medicaid Services – Autism Speaks Refined developed through discussions with key informants, TEP, public comment, review Employed comprehensive search strategy Extracted data and assessed study quality

48 Key Questions KQ1. Clinical outcome: What are the the short- and long- term effects of available behavioral, medical, allied health, or CAM treatment approaches? Core features Associated characteristics KQ2. Modifiers: What are the modifiers of outcome for different treatments or approaches? KQ3. Early Response to Treatment: Are there any identifiable changes early in the treatment phase that predict treatment outcomes? KQ4. Functional Outcomes: What is the evidence that effects measured at the end of the treatment phase predict long-term functional outcomes? 48

49 Key Questions KQ5. Generalization: What is the evidence that specific intervention effects measured in the treatment context generalize to other contexts? KQ6. What Drives Treatment: What evidence supports specific components of treatment as driving outcomes, either within a single treatment or across treatments? KQ7. Earliest Intervention: What evidence supports the use of a specific treatment approach in children under the age of two who are at high risk of developing autism based upon behavioral, medical, or genetic risk factors? 49

50 Methods MEDLINE ®, ERIC and PsycInfo ®, reference lists Included studies – January 2000 – May 2010 DSM-IV-TR, ADOS, ADI – n >30 medical / n > 10 behavioral Dual review of abstracts Extracted clinical data to standardized forms Two reviewers quality assessed each study – Studies rated as good, fair, or poor Overall strength of evidence assessed using EPC Methods Guide for Effectiveness and Comparative Effectiveness Reviews – Strength of evidence presented as insufficient, low, moderate, or high 50

51 Quality Assessment Study design – Group design / Appropriate comparison – Random assignment / Appropriateness Diagnostic approach – Standardized within study approach – ADOS/ADI/CBE Participant ascertainment – Developmental/cognitive/ language/severity – Inclusion / exclusion Intervention characteristics – Was the intervention fully described? – Was treatment fidelity or adherence measured? Outcomes measurement – Reliable/valid measures – Blind coding Statistical analysis – Appropriateness of analysis

52 Strength of Evidence Assessment of literature done by considering both the observed effectiveness of interventions and confidence in the stability of those effects in the face of future research. Assessment based on consideration of four domains: – Risk of bias – Consistency in direction of the effect – limitations of 1 – Directness in measuring intended outcomes – Precision of effect

53 Strength of Evidence – High: High confidence that the evidence reflects the true effect. Further research is unlikely to change estimates. – Moderate: Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate. – Low: Low confidence that the evidence reflects the true effect. Further research is likely to change confidence in the estimate of effect and is also likely to change the estimate. – Insufficient: Evidence is either unavailable or does not permit a conclusion.

54 Literature Review Results Abstracts reviewed: 4,120 Full text studies reviewed: 714 Full text studies retained: 159 – 78 - Behavioral early intervention, social skills interventions, CBT, play/interaction- based approaches – 15 - Educational broad-based approaches in educational setting, computer-based approaches, TEACCH – 42 - Medical studies: antipsychotics, SRIs, stimulants, secretin, diets, supplements, hyperbaric oxygen, chelation, other medical – 17 - Allied health studies: speech/language, sensory and auditory integration, recreational and other approaches – 7 - CAM studies massage and acupuncture

55 Highlighting Categories of Intervention For many children behavioral interventions form the core of treatment – Early intensive behavioral and developmental interventions A striking number of children with ASD are treated with medical interventions – Psychopharmacology – Other medical treatments (diets, supplements, injections)

56 Early Intensive Behavioral and Developmental Interventions (EIBDI) Comprehensive (see Rogers and Vismara, 2008) – Focus on several areas of functioning vs. skill specific intervention Draw from principles of Applied Behavior Analysis (ABA) – Method and setting ABA umbrella term for learning principles/techniques Teach new behaviors, reduce challenging behaviors Systematic reinforcement ABA is a term existing for decades prior to specific adoption within autism intervention literature

57 EIBDI Literature 34 studies addressing EIBDI: – 1 good – 12 fair – 21 poor quality

58 Early intensive behavioral and developmental interventions UCLA/Lovaas model & variants: – Intensive intervention (18-36 hr) utilizing operant conditioning, emphasis on structure and discrete trial toward generalization of skills – Variants of Early Intensive Behavioral Intervention (EIBI) – Is this a category? Comprehensive approaches for children under 2: – ABA principles within a developmental and relational framework – Early Start Denver Model (ESDM) / Early social communication training – Range: Intensive intervention (15-20 hours) to lower levels Parent-training: – Pivotal Response Training, Social Pragmatic Intervention, More than Words, etc.

59 Key Findings-UCLA/Lovaas and Variants Design: – 1 RCT / fair quality – 3 nRCT / fair quality – 3 prospective cohort / fair quality – Poor: 2 prospective cohort, 2 retrospective cohort, 6 prospective case series 6 retrospective case series Treatment: – 4/7 utilizing manualized approach in some form – Intensity: 18 – 36/40 hours – Duration =.75 – 4 years – Comparisons to community, parent, training, low intensity Sample – Assignment often upon availability, parent decisions – Preschoolers (i.e., typically > 3 years; range - 29-63 months) – Basal IQ = 54 – 76 NO STUDIES MADE THE SAME COMPARISONS IN TERMS OF INTERVENTIONS AND POPULATIONS

60 Smith (2000): An attempt to replicate Lovaas’ original work N=28; IQ = 51 (35-75); Age= 36 months (18-42); absence of med problems Intervention: 25 hrs/week individual treatment (1st yr; <2nd yr) Comparator: parent training over 3-9 months Results: Mean IQ increase 15 pts, no change in control 4/15 unsupported educational placements Largest gains in PDD-NOS relative to Autistic D/O No group differences in adaptive or challenging behavior 60 UCLA/Lovaas: The RCT of fair quality

61 Key Findings-UCLA/Lovaas and Variants Our Fair Studies StudyYearN EIBI hrs Basal IQ IQ Shift Educational PlacementAdaptive Zachor20073935762NR Reed200748NR5613NR13 Smith*+2000282551164/15-2 Hayward*200944365417NR6 Cohen*20064235-4062256/2120 Eikeseth*2002251863250/1312 Howard20056135-405930NR11

62 Key Findings-UCLA/Lovaas and Variants: Young preschool children receiving high intensity interventions over extended durations (18-36) hours a week for extended durations (1-3) years by well-trained therapists) Improvements in areas of cognitive, language, adaptive functioning Extremely variable range of outcomes within and across these domains Subgroups of children appear to display differentiated response to this intervention, but the subgroups with moderated/positive response are not well characterized Low SOE: language, cognitive, educational, adaptive outcomes, ASD symptom severity

63 Dawson (2010): Manualized intervention for young children N=48 IQ = 60 (35-75) Age= 23 months at entry Intervention: 20 hrs/week, 5/parent, + community Comparator: Community care (18 hrs: 9 individual + 9 group) 63 Early Start Denver Model: An RCT of good quality

64 Results: Mean IQ increase 17.6 pts, to 7.0 for control Trend toward less decline in adaptive behavior (-.8 vs -11.2) ADOS severity scores or challenging behavior scores not different Shifts in diagnosis within category? (PDD <- AD) Comment: Cohort continues to be followed; receive treatment 64 Early Start Denver Model: Outcomes

65 Summary: Early Intensive Intervention for ASD Individual studies document positive outcomes from a variety of approaches in cognitive performance, language, adaptive behavior when delivered intensively over substantial intervals of time Subset of individuals demonstrating tremendous response/plasticity Variability / heterogeneity tremendous – Change related to core, associated features Response (i.e., moderated vs. rapid) Limited understanding of subgroups – Approaches utilized / outcomes assessed Highly specified individualized treatments not yet identifiable – Predictions of early response -> Movement to other models – The value of moderated response?

66 Medical Interventions Some 3/4 of individuals with ASD receiving psychotropic medication in past year (Esbensen, 2009) Multiple psychotropic medication use common Majority (30-70%) of individuals within ASD clinics report complementary and alternative medical interventions (see Levy & Hyman, 2011)

67 Autism Spectrum Disorders (ASD)

68 Overview of Medical and Related Treatment 42 unique studies addressing medical interventions – 27 RCT(s) – 9 Prospective Case Series – 6 Retrospective Case Series Quality: 9 good, 18 fair, 15 poor Categorized as antipsychotics; serotonin reuptake inhibitors; stimulants and other medications for hyperactivity; secretin; and dietary and other interventions

69 Antipsychotic Medications Aripiprazole = high SOE Risperidone = moderate SOE Primary target symptoms: ‘Irritability’ subscale of Aberrant Behavior Checklist – Originally ‘irritability/agitation/crying’ Also show significant benefit on ‘Hyperactivity/defiance’ and ‘Stereotyped behavior’ subscales Warren et al., AHRQ, 2011

70 Antipsychotic medications Significant side effects: – Weight gain – Sedation – Extrapyramidal symptoms

71 Secretin High SOE for lack of efficacy Lesson to be learned: – Hesitate to draw conclusions from open label studies or case series before randomized controlled trials have been performed

72 All other medications Insufficient Strength of Evidence – Stimulants Methylphenidate RCT suggests less benefit, more side effects than in ADHD (RUPP, 2006) – Serotonin reuptake inhibitors Citalopram RCT shows no benefit in overall ratings, no benefit for repetitive behaviors, slight improvement in ABC ‘irritability’ Fluoxetine cross-over RCT shows possible benefit for OCD-like symptoms

73 Summary Antipsychotic medications help with comorbid irritability/agitation Stimulants are promising for hyperactivity Combined, refined, targeted behavioral an psychopharacological interventions may be necessary

74 Other medications under study… Oxytocin mGluR5 antagonists / GABA-B agonists (Fr.X) Guanfacine (alpha agonist) Memantine (NMDA antagonist) Riluzole (anti-glutamatergic) N-acetylcysteine (antioxidant, pro-GABA) Buspirone (5-HT 1A agonist, etc.) Minocycline (Matrix metalloproteinase inhibitor)

75 Conclusions Evidence for early intensive behavioral and developmental intervention: – Evidence for improvements: cognitive, language, adaptive behavior for some children – Subgroups of rapid gain may drive effects Robust gains / continued impairment Moderated response / quality of life improvement – Impact on core features -> functional meaningful distal outcomes – No studies directly compare models – vary widely in approach – Need replication/extension of models given current evidence – Small samples, poor comparisons, heterogeneity within/across studies interventions/outcomes, effectiveness/feasibility

76 Conclusions Some medications may benefit some behaviors of children with ASD: – Risperidone and Aripiprizole – problem and repetitive behavior – Strong evidence for adverse effects – Limited evidence for impact on core ASD features / impairments – Need further research on many medical interventions: SRIs, methylphenidate, omega 3 fatty acids, melatonin – Some medical interventions clearly not efficacious - secretin – Even though in wide use, poorly studied

77 Unanswered Questions Moderators: Few studies appropriated designed or powered – One study of RPMT / PECS – Object exploration / joint attention – IQ / language, age, social responsiveness, imitation subtypes Early change predicting outcome: – Little information – Change in IQ? Functional change/Generalization: – Limited investigation – Some outcomes are likely to represent generalization by report Key Drivers – No specific studies identified

78 Other approaches Practice statements / Reviews: – National Autism Center /National Standards Project (2010): Established Treatments – Reichow and Wolery, 2009 - EIBI review and meta-analysis – Evaluative Method for Evaluating and Determining Evidence-Based Practices in Autism (Reichow, Volkmar, Cicchetti, 2007) – Rogers and Vismara, 2008 - Comprehensive treatments APA Division 12 – Well-established, probable/possible efficacious – National Research Council, 2001 Little evidence to support one treatment over another Effective treatments share many features in common Focus on these commonalities to address core deficit areas

Download ppt "Update of Autism Evaluation, Treatment, and Research Zachary Warren, PhD, Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum."

Similar presentations

Ads by Google